Author: Deerfield Group

Posted Date:

April 28, 2026

HERVolution Therapeutics Appoints Dr. László B. Tankó to Scientific Advisory Board to Strengthen Cardiometabolic Clinical Development Strategy

Deerfield Group

April 28, 2026
Deerfield Group Launches Prismatiq™, an Intuitive Field Enablement Platform Purpose-Built for Life Sciences

Deerfield Group

April 22, 2026
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

Deerfield Group

April 17, 2026
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

Deerfield Group

April 17, 2026
Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026

Deerfield Group

April 17, 2026
AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension

Deerfield Group

April 9, 2026
Deerfield Group Names Bill Veltre as Chief Media Officer

Deerfield Group

April 9, 2026
Accent Therapeutics to Present Preclinical Data on Lead Clinical Program, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting

Deerfield Group

April 2, 2026
Petrichor Names Paul Sekhri as Operating Partner

Deerfield Group

April 1, 2026
Averna Therapeutics Announces Strategic Leadership Expansion

Deerfield Group

March 26, 2026